Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Techniclone initiates phase II trial for treatment of malignant glioma

Dec. 9, 1998

No Comments

CMA-676 shows efficacy and excellent tolerability in patients with AML

Dec. 9, 1998

No Comments

Excellent results obtained in AML patients receiving Maxamine plus IL-2

Dec. 9, 1998

No Comments

U.S. patent covers Coulter's antibody therapy for B-cell lymphoma

Dec. 9, 1998

No Comments

Biomira initiates pivotal phase III trial of Theratope vaccine

Dec. 7, 1998

No Comments

Maxamine Therapy enters phase II trial for late-stage RCC

Dec. 4, 1998

No Comments

Coulter and SB enter agreement to develop and commercialize I-131 anti-B1 antibody

Dec. 4, 1998

No Comments

Enrollment completed in phase I Biomira lung cancer vaccine trial

Dec. 4, 1998

No Comments

MDX-210 demonstrates antitumor activity in phase II studies

Dec. 4, 1998

No Comments

Vical provides clinical update of Leuvectin in treatment of prostate cancer

Dec. 2, 1998

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Immuno-oncology
RSS

Techniclone initiates phase II trial for treatment of malignant glioma

CMA-676 shows efficacy and excellent tolerability in patients with AML

Excellent results obtained in AML patients receiving Maxamine plus IL-2

U.S. patent covers Coulter's antibody therapy for B-cell lymphoma

Biomira initiates pivotal phase III trial of Theratope vaccine

Maxamine Therapy enters phase II trial for late-stage RCC

Coulter and SB enter agreement to develop and commercialize I-131 anti-B1 antibody

Enrollment completed in phase I Biomira lung cancer vaccine trial

MDX-210 demonstrates antitumor activity in phase II studies

Vical provides clinical update of Leuvectin in treatment of prostate cancer

Today's news in brief

Today's news in brief

STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space

GLP-1 receptor agonists continue their global victory tour

AI drives financings, approvals for APAC med-tech in 2024

Immuno-oncology RSS

Immuno-oncology
RSS